Effect of the efficacy and safety of trastuzumab combined with docetaxel chemotherapy in stage Ⅲ breast cancer
10.3969/j.issn.1005-1678.2017.04.011
- VernacularTitle:曲妥珠单抗联合多西他赛化疗对Ⅲ期乳腺癌患者的治疗效果及安全性的影响
- Author:
Qi LI
;
Weizhu WU
- Keywords:
trastuzumab;
docetaxel;
breast cancer;
clinical efficacy;
safety
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(4):34-36,39
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and safety of trastuzumab combined with docetaxel chemotherapy in the treatment of stage Ⅲ breast cancer.Methods 150 cases of stage Ⅲ breast cancer patients from October 2013 to September 2015 in our hospital were selected and randomly divided into experimental group and control group,75 cases in each group,the control group were treated with cyclophosphamide and doxorubicin treatment,experimental group were treated with trastuzumab combined with docetaxel chemotherapy.To 21 days for a course of treatment,all patients were treated three courses.The levels of serum C reactive protein(C-reactive protein,CRP),the total effective rate and the incidence of adverse reactions in two groups before and after treatment were compared.Results After treatment,the level of serum CRP in the two groups decreased significantly,the difference was statistically significant(P<0.05),the CRP levels of serum in experimental group was significantly lower than the control group,the difference was statistically significant(P<0.05),the clinical total effective rate is higher,the difference was statistically significant(P<0.05),the incidence rate of adverse reaction was lower,the difference was statistically significant(P<0.05).Conclusion Trastuzumab combined with docetaxel chemotherapy can effectively reduce the inflammatory response in patients with stage Ⅲ breast cancer,improve clinical efficacy,and effectively reduce the adverse reactions of patients.
